Elevate your local knowledge
Sign up for the iNFOnews newsletter today!

WHITEHOUSE STATION, N.J. – Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.
Merck’s first-quarter profit fell 8.3 per cent and revenue by 9 per cent, mainly because competition from generics slashed sales of its top seller, asthma and allergy drug Singulair.
The Whitehouse Station, N.J. company says net income was $1.59 billion, or 52 cents per share, down from $1.74 billion, or 56 cents per share, a year earlier.
Adjusted earnings were 85 cents per share, a nickel more than analysts expected.
Revenue totalled $10.67 billion, down from $11.73 billion. Analysts expected $11.11 billion.
Merck shares fell 99 cents to $46.01 in premarket trading.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.